Applied Digital Solutions, though its subsidiary VeriChip Corporation has announced today that the U.S. Patent and Trademark Office has granted VeriChip Corp. a patent for its portable RFID asset
MedImmune issued the following statement regarding today's U.S. Supreme Court decision in MedImmune, Inc. vs. Genentech, Inc. et al.: By granting MedImmune's appeal, the U.S. Supr
Ryogen LLC announced today that the company have entered into a nonexclusive license agreement with Invitrogen Corporation, whereby Invitrogen has licensed from Ryogen the patent directed to the clinic
CogState has announced that it has been issued a patent from the Unites States Patent & Trade Mark Office (US patent no. 7,163,513) for the key technology platform used in its computer-based tests
Acusphere, Inc. announced today the issuance of U.S. Patent No. 7,160,557 B2, entitled "Matrices Formed of Polymer and Hydrophobic Compounds for Use in Drug Delivery." The patent covers the s
Nanion Technologies GmbH, a supplier of automated, parallel patch-clamp systems based in Munich, Germany, has announced that they would appeal the decision of the European Patent Office (EPO) to uphold t
Heska Corporation has announced that it has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liqu
Nano Chemical Systems announced today that it has filed a US Patent application on a breakthrough new material that exhibits light (luminescent) in the absence of heat. This Nano-enhanced
Ranbaxy Laboratories Limited announced that the Federal Court of Canada has handed down a favorable decision in the company's case against Pfizer by finding invalid Pfizer's Canadian atorvastatin pate
The lawsuit is the result of a Paragraph IV Certification letter submitted by Andrx to AstraZeneca concerning its intent to manufacture and sell metoprolol succinate in the 25 mg dose form in the United States. Metoprolol succinate is marketed as TOPROL-XL(R) in the U.S. by AstraZeneca, LP. The basis for AstraZeneca's complaint is that the action taken by Andrx infringes AstraZeneca's patents covering TOPROL-XL.
In February of this year, AstraZeneca filed suit against Andrx for patent infringement for the 50 mg dose form of TOPROL-XL. Additionally, AstraZeneca filed suit in May of 2003 against KV Pharmaceuticals for patent infringement for the 200 mg dose form and again in August of 2003 for patent infringement for the 100 mg dose form. In 2003, TOPROL-XL had U.S. sales of $909m. Of these sales, approximately 15% were in the 25 mg dosage.
http://www.astrazeneca-us.com/